Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Autor:	Gonzalez-Alonso P; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Cristobal I; Medical Oncology Department, Oncohealth Institute, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Zazo S; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Martin-Aparicio E; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Chamizo C; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Madoz-Gurpide J; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Rovira A; Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain., Eroles P; Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain., Lluch A; Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain., Albanell J; Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain., Rojo F; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Current medicinal chemistry [Curr Med Chem] 2018; Vol. 25 (17), pp. 1976-1998.
DOI:	10.2174/0929867323666161216144659
Abstrakt:	Background: Overexpression and amplification of the human epidermal growth factor receptor 2 (HER2) occur in 20% of total breast carcinomas. HER2-overexpression is implicated in disease initiation and progression and associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody, is the standard HER2-targeted therapy for early and metastatic HER2-amplified breast cancer patients. Trastuzumab has significantly increased clinical benefit in HER2+ metastatic and adjuvant settings; however, it is not effective for many patients due to primary or acquired resistance to the drug. During the last decade, many studies have revealed a number of novel molecular traits of HER2+ breast cancer, allowing us to uncover the molecular mechanisms involved in trastuzumab resistance and develop strategies to overcome resistance to therapy. Objective: In this review, we comprehensively addressed the current achievements in preclinical studies; we discussed molecular mechanisms of acquired trastuzumab resistance in HER2+ breast cancer models and potential therapeutic approaches based on the molecular features for HER2+ breast cancer. Conclusion: Enhanced understanding of the molecular profiles in HER2+ breast cancer may lead to the identification of novel biomarkers for the development of diagnostic approaches and improvement of therapeutic targets for the prevention and treatment of trastuzumab resistant HER2+ breast cancer. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu